Only 503A pharmacies are covered, and one Florida compounder says the whole sector couldn't meet demand. Public Citizen says Kennedy undermined the FDA.
Recap by typeshit. Full story at Houston Public Media.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
Law firm Frier Levitt reads the rule as single-ingredient only, so the popular blend stays out. Public Citizen and ex-FDA official Janet Woodcock voice safety concerns.
Six peptides can now be compounded under strict conditions, but HHS itself says that proves nothing on safety, and research-use-only sellers stay outside the policy.
Compounders get a pass on BPC-157, TB-500 and four others if they meet sourcing and reporting rules. The Alliance for Pharmacy Compounding cheers it, while Public Citizen calls it reckless.
The once-daily tablet also trimmed weight about 4% over 13 weeks, with no dropouts from stomach side effects, the company reports. Obesity phase III data are due in 2028.
The cash flow estimate points to the retatrutide phase 3 win and a deeper pipeline as reasons Lilly's value could sit above today's share price.
Loading…